Gå direkt till huvudinnehållet

Allergi mot grönsaker – kostvägledning

Senast uppdaterad: Senast reviderad:
Sakkunnig:

  1. Nowak-Węgrzyn A. Pathogenesis of oral allergy syndrome (pollen-food allergy syndrome). UpToDate, last updated July 17, 2012 www.uptodate.com  
  2. Lack GT, Fox D, Northstone K, Golding J. Factors associated with the development of peanut allergy in childhood. N Engl J Med 2003; 348: 977-85. PubMed  
  3. Asarnoj A, Movérare R, Ostblom E, et al. IgE to peanut allergen components: relation to peanut symptoms and pollen sensitization in 8-year-olds. Allergy. 2010 Sep;65(9):1189-95. PMID: 20146729. PubMed  
  4. Maloney JM, Rudengren M, Ahlstedt S, et al. The use of serum-specific IgE measurements for the diagnosis of peanut, tree nut, and seed allergy. J Allergy Clin Immunol 2008; 122: 145. pmid:18502490 PubMed  
  5. Toit GD, Roberts G, Sayre PH, et al. Randomized trial of peanut comsumption infants at risk for peanut allergy. N Engl J Med 2015; 372: 803-13. pmid: 25705822 PubMed  
  6. Toit GD, Sayre PH, Roberts G, et al. Effect of avoidance on peanut allergy after early peanut consumption. N Engl J Med 2016. doi:10.1056/NEJMoa1514209 DOI  
  7. Greenhawt M. The Learning Early About Peanut Allergy Study: The Benefits of Early Peanut Introduction, and a New Horizon in Fighting the Food Allergy Epidemic. Pediatr Clin North Am 2015 Dec; 62(6): 1509-21. doi:10.1016/j.pcl.2015.07.010 DOI  
  8. Clark AT, Islam S, King Y, et al. Successful oral tolerance inductionin severe peanutallergy. Allergy 2009; 64: 1218-20. PubMed  
  9. Jones SM, Pons L, Roberts JL, et al. Clinical efficacy and immune regulation with peanut oral immunotherapy. J Allergy Clin Immunol 2009; 124: 292-300. PubMed  
  10. Anagnostou K, Islam S, King Y, et al. Assessing the efficacy of oral immunotherapy for the desensitisation of peanut allergy in children (STOP II): a phase 2 randomised controlled trial. Lancet 2014. doi:10.1016/S0140-6736(13)62301-6 DOI  
  11. The PALISADE Group of Clinical Investigator: Vickery BP, Vereda A, Casale TB, et al. AR101 Oral Immunotherapy for Peanut Allergy. N Engl J Med 2018. pmid:30449234 PubMed  
  12. Chinthrajah RS, Purington N, Andorf S, et al. Sustained outcomes in oral immunotherapy for peanut allergy (POISED study): a large, randomised, double-blind, placebo-controlled, phase 2 study. Lancet 2019. pmid:31522849 PubMed  
  13. Jones SM, Kim EH, Nadeau KC, et al. Efficacy and safety of oral immunotherapy in children aged 1–3 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled study. Lancet 2022; 399: 359-371. doi:10.1016/S0140-6736(21)02390-4 DOI  
  14. Chu DK, Wood RA, French S, et al. Oral immunotherapy for peanut allergy (PACE): a systematic review and meta-analysis of efficacy and safety. Lancet 2019; 399: 2222-32. pmid:31030987 PubMed  
  15. Fleischer DM, Greenhawt M, Sussman G, et al. Effect of epicutaneous immunotherapy vs placebo on reaction to peanut ingestion among children with peanut allergy. The PEPITES randomized clinical trial. JAMA 2019. pmid:30794314 PubMed  
  • Anna Nager, med dr och specialist i allmänmedicin, Karolinska institutet

Tidigare sakkunniga

  • Nils E Eriksson, docent och fd överläkare, Lung- och allergimottagningen, Halmstad